Skip to main content

12.07.2016 | SCLC | Online-Artikel

ULTIMATE: chemotherapy plus bevacizumab beyond first line

Figure: Progression-free survival with paclitaxel plus bevacizumab versus docetaxel

Weiterführende Themen